The FDA has approved Sanofi’s Sarclisa (siltuximab) in combination with VRd as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. This approval makes Sarclisa the first anti-CD38 therapy in combination with VRd to significantly reduce disease progression or death in this patient population.